Abstract

The sarco(endo)plasmic reticulum calcium ATPase (SERCA) is regulated in a tissue-dependent manner via interaction with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN). Although defects in SERCA activity are known to cause heart failure, the regulatory mechanisms imposed by PLN and SLN could have clinical implications for both heart and skeletal muscle diseases. PLN and SLN have significant sequence homology in their transmembrane regions, suggesting a similar mode of binding to SERCA. However, unlike PLN, SLN has a conserved C-terminal luminal tail composed of five amino acids ((27)RSYQY), which may contribute to a distinct SERCA regulatory mechanism. We have functionally characterized alanine mutants of the C-terminal tail of SLN using co-reconstituted proteoliposomes of SERCA and SLN. We found that Arg(27) and Tyr(31) are essential for SLN function. We also tested the effect of a truncated variant of SLN (Arg(27)stop) and extended chimeras of PLN with the five luminal residues of SLN added to its C terminus. The Arg(27)stop form of SLN resulted in loss of function, whereas the PLN chimeras resulted in superinhibition with characteristics of both PLN and SLN. Based on our results, we propose that the C-terminal tail of SLN is a distinct, essential domain in the regulation of SERCA and that the functional properties of the SLN tail can be transferred to PLN.

Highlights

  • Sarcolipin is a regulator of sarco(endo)plasmic reticulum calcium ATPase (SERCA) in skeletal and atrial muscle with inhibitory properties thought to be similar to phospholamban

  • Comparative data for PLN indicated that it lowers the apparent calcium affinity of SERCA to a degree similar to that of SLN, and it has the opposite effect on Vmax

  • As an endogenous inhibitor of SERCA, SLN plays a central role in regulating calcium transport in skeletal muscle

Read more

Summary

Background

Sarcolipin is a regulator of SERCA in skeletal and atrial muscle with inhibitory properties thought to be similar to phospholamban. Given the highly conserved nature of the SLN luminal tail and our incomplete understanding of its role in SERCA inhibition, we chose to investigate this domain by the co-reconstitution of SLN mutants with SERCA into proteoliposomes Another motivating factor for this study was the observation that PLN and SLN can simultaneously bind to and regulate SERCA [7]. Superinhibition is thought to result from the tight fit of both PLN and SLN in the SERCA binding groove (M2, M4, M6, and M9), we hypothesized that the luminal domain of SLN may contribute to the strong inhibitory properties of the ternary complex. This prompted us to investigate chimeric PLN-SLN constructs. We conclude that the highly conserved C-terminal tail of SLN is a primary determinant for SERCA inhibition and that it is a distinct and transferrable functional domain

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.